IP Library Granted Patent US 8,939,971
Granted Patent B2
US 8,939,971 · App. 13/416,791 · Granted Jan 27, 2015

System and method for endometrial ablation

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,939,971
App. No.
13/416,791
Granted
Jan 27, 2015
Kind
B2
Abstract

Methods, systems and devices for evaluating the integrity of a uterine cavity. A method comprises introducing transcervically a probe into a patient's uterine cavity, providing a flow of a fluid (e.g., CO 2 ) through the probe into the uterine cavity and monitoring the rate of the flow to characterize the uterine cavity as perforated or non-perforated based on a change in the flow rate.

Claims (15)

1. A medical method for ablating tissue, comprising:

creating a negative pressure in a neutral gas in a fluid-tight chamber of a dielectric positioned adjacent to targeted tissue;

applying RF energy to ignite and maintain a plasma in the negative pressure neutral gas;

adjusting the negative pressure toward an ambient pressure while maintaining the plasma, wherein the dielectric delivers energy to the targeted tissue.

2. The method of claim 1 wherein creating the negative pressure is initiated at between −0.25 psig and −10 psig.

3. The method of claim 1 wherein creating the negative pressure is initiated at between −0.5 psig and −5 psig.

4. The method of claim 1 further comprising terminating the negative pressure after initiating RF application.

5. The method of claim 4 wherein terminating the negative pressure occurs between 0.1 and 10 seconds after initiating RF application.

6. The method of claim 1 wherein the applying step applies at least 150 volts.

7. The method of claim 6 wherein applying at least 150 volts occurs for less than 10 seconds, less than 5 seconds or less than 2 seconds.

8. The method of claim 1 wherein the applying step includes a voltage spike of at least 150 volts to initiate plasma followed by a plasma-maintaining voltage to maintain the plasma over a treatment interval.

9. The method of claim 1 wherein the adjusting step includes adjusting the pressure to a positive pressure.

10. The method of claim 9 wherein the positive pressure is at least +0.1 psig.

11. The method of claim 9 wherein the positive pressure is in the range of +0.5 psig to 10 psig.

12. The method of claim 1 wherein the creating step includes an initial stage that creates a negative pressure that is below −5 psig in the fluid-tight chamber of the dielectric positioned outside a patient's body to facilitate trans-cervical introduction of the dielectric.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 12, 2026
From: MINERVA SURGICAL, INC.
To: AXORA MEDICAL, INC.
Reel/Frame 075561/0186 →
RELEASE OF SECURITY INTEREST Recorded Feb 5, 2026
From: CANADIAN IMPERIAL BANK OF COMMERCE
To: MINERVA SURGICAL, INC.
Reel/Frame 074721/0585 →
SECURITY INTEREST Recorded Jan 30, 2026
From: AXORA MEDICAL, INC.
To: SYMBIOTIC CAPITAL AGENCY LLC, AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT
Reel/Frame 074537/0617 →
RELEASE OF SECURITY INTEREST Recorded Oct 12, 2021
From: ARES CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
To: MINERVA SURGICAL, INC.
Reel/Frame 057770/0451 →
SECURITY INTEREST Recorded Oct 8, 2021
From: MINERVA SURGICAL, INC.
To: CANADIAN IMPERIAL BANK OF COMMERCE
Reel/Frame 057758/0137 →
SECURITY INTEREST Recorded Dec 31, 2019
From: MINERVA SURGICAL, INC.
To: ARES CAPITAL CORPORATION
Reel/Frame 051395/0275 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 20, 2019
From: TRUCKAI, CSABA; BEK, ROBIN; TOTH, AKOS
To: MINERVA SURGICAL, INC.
Reel/Frame 051345/0280 →